Skip to content
‹ Back to IndustriesSciences

Expert Compares SpaceX and Bezos’ Blue Origin Space Race to the Tortoise and the Hare

Brad Stone, the author of “Amazon Unbound“, compares Elon Musk’s SpaceX to Jeff Bezos’s Blue Origin — referring to them as the tortoise and the hare. But what else separates the two intergalactic competitors? Who will eventually win the space race? Watch below for more. Host: It’s hard to believe that Blue Origin is actually…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences · · Blue OriginBrad StoneElon MuskJeff Bezos
Share

Key takeaways

01

Brad Stone, the author of “Amazon Unbound“, compares Elon Musk’s SpaceX to Jeff Bezos’s Blue Origin — referring to them as the tortoise and the hare.

02

But what else separates the two intergalactic competitors?

03

Who will eventually win the space race?

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

Brad Stone, the author of “Amazon Unbound“, compares Elon Musk’s SpaceX to Jeff Bezos’s Blue Origin — referring to them as the tortoise and the hare. But what else separates the two intergalactic competitors? Who will eventually win the space race? Watch below for more.

Host: It’s hard to believe that Blue Origin is actually more than 20 years old and now they’re just getting to their first human launch, but how is Blue Origin different from SpaceX? And how is Elon Musk different from Jeff Bezos?

Stone: It’s incredible. In the empire of accomplishment, Blue Origin for Jeff Bezos is kind of, you know, the tarnished jewel, at least right now.

Host: The ugly stepchild?

Stone: Or let me put it. Let me use the word, the metaphor they use. It’s the tortoise and not the hare.

He always wanted to go slow. He wanted to constrain the investment. He wanted to keep the team small, and he wanted to move step by step.

And so suborbital or the edge of space and bringing tourists. There was going to be the first step. And then they would get to orbit and then they would go to the moon.

And what happened was the hare came along. Elon comes along, finances it with venture capital and then government contracts and gets all the glory. And they do quite well.

And I think Bezos has a fair amount of I don’t know if jealousy is the right word, but curiosity that here Elon is getting paid by the government to launch and he is still funding Blue Origin to the tune of a billion in Amazon stock every year. And so we’ve seen Bezos accelerate blue origin’s timetable, its ambitions, its timeline, and see it a little bit of dysfunction over the past few years. And so far, there hasn’t been a lot to show for it.

*Bloomberg contributed to this content

—

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Video TranscriptExpand ↓

Hard to believe that Blue Origin is actually more than 20 years old and now they're just getting to their first human launch, but how is Blue Origin different from space? And how is Elon Musk different from Jeff bezos? It's incredible. In the empire of accomplishment, Blue Origin for Jeff Bezos is kind of, you know, the tarnished jewel, at least right now, the ugly stepchild. Or let me put it. Let me use the word, the metaphor they use. It's the tortoise and not the hair. He always wanted to go slow. He wanted to constrain the investment. He wanted to keep the team small, and he wanted to move step by step. And so suborbital or the edge of space and bringing tourists. There was going to be the first step. And then they would get to orbit and then they would go to the moon. And what happened was the hare came along. Elon comes along, finances it with venture capital and then government contracts and gets all the glory. And they do quite well. And I think Bezos has a fair amount of I don't know if jealousy is the right word, but curiosity that here Elon is getting paid by the government to launch and he is still funding Blue Origin to the tune of a billion in Amazon stock every year. And so we've seen Bezos accelerate blue origin's timetable, its ambitions, its timeline, and see it a little bit of dysfunction over the past few years. And so far, there hasn't been a lot to show for it.

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

S
Sciences
B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

Antibody developability checks are moving into discovery instead of waiting for development

Antibody developability checks are moving into discovery instead of waiting for development

Maria Gonzalez-Pajuelo of FairJourney Bio says the order in antibody discovery is changing: developability has become a much more important consideration during discovery, rather than an issue left until later-stage development. The goal, she says, is that what comes out of discovery is something CMC can take forward easily.

  • 01Discovery-stage developability screens can rank many antibodies tested once or twice and may reduce surprises later in development, while development still focuses on several lots of a single antibody and answers different questions.

Oct 1, 2026

Caraballo expects AI across all five tracks at ISPE’s 2026 Annual Meeting

Caraballo expects AI across all five tracks at ISPE’s 2026 Annual Meeting

ISPE’s 2026 Annual Meeting and Expo in Washington, DC organizes its program around five tracks running from discovery to governance, with international program committee chair Connie Langer of Pfizer Global Supply and executive chair Jose Caraballo of JCO Global Advisory LLC describing how the tracks connect—and why AI is treated as a cross-cutting topic rather than a standalone track. Deloitte’s December 2025 survey of 280 executives frames the mood the program is built for.

  • 01ISPE’s 2026 Annual Meeting has no dedicated AI track; executive chair Jose Caraballo expects AI presentations across all five tracks, from discovery to governance.
  • 02Deloitte’s December 2025 survey of 280 biopharma and medtech C-suite executives found more than 75% confident in their own outlook but only 41% optimistic about the global economy, a mood the story says the ISPE chairs are programming for.
  • 03A staffing firm reports life sciences job openings falling even as digital fluency becomes a required skill, so the upskilling burden lands on the people already employed, which is where the mandatory, university-partnered AI training Connie Langer describes at her company sits.

Sep 30, 2026

Crown Bioscience's San Diego site fits the tumor model to the therapy, not the reverse

Crown Bioscience's San Diego site fits the tumor model to the therapy, not the reverse

Crown Bioscience's San Diego site designs preclinical tumor models to match specific therapies and delivery routes, rather than forcing treatments into standard study designs. It combines custom surgical procedures, cell line-derived xenografts, patient-derived xenografts (including post-treatment models), and biomarker capabilities to generate translational data that can help sponsors decide whether to advance a program.

  • 01Orthotopic brain tumor implantation using tagged models lets researchers track tumor growth in the original organ, aligning the model and delivery route with how therapies are intended to be tested.
  • 02Patient-derived xenografts developed from tumors after prior treatment may better reflect progressed disease, helping teams study therapies aimed at patients whose cancer has advanced after earlier treatment.
  • 03Combining biomarker analysis of preclinical model samples with clinical sample testing at one site could make it easier to connect what is measured in animals with what is later measured in patients.

Sep 30, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512